What is the 13F Pro Quality Score for JBIO?

13F Pro ranks Jade Biosciences, Inc. (JBIO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View JBIO's current score at https://13fpro.ai/research/JBIO (free sign-up required for the full ranking).

Which hedge funds own the most JBIO stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of JBIO include FMR, Fairmount Funds Management, RA CAPITAL MANAGEMENT, L.P.. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/JBIO as soon as new 13F filings post.

Where does 13F Pro source JBIO data?

All Jade Biosciences, Inc. fundamentals and ownership data come directly from SEC EDGAR. Jade Biosciences, Inc. files with the SEC under CIK 1798749. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is JBIO in?

Jade Biosciences, Inc. (JBIO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is JBIO research updated on 13F Pro?

JBIO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Jade Biosciences, Inc.(JBIO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1798749 JBIO stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

JBIO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Jade Biosciences, Inc. (JBIO), a Healthcare sector company. JBIO is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Jade Biosciences, Inc. reports net income of $-40.4M, free cash flow of $-24.1M. Top institutional holders of JBIO by reported 13-F value include FMR, Fairmount Funds Management, RA CAPITAL MANAGEMENT, L.P., based on the most recent SEC filings. JBIO trades on the Nasdaq exchange and files with the SEC under CIK 1798749. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate JBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Jade Biosciences, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-40.4M

Free Cash Flow

Q1 2026

$-24.1M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-83.0% YoY

$-127.4MFY 2025

FY21 $-23.0MFY22 $-51.5MFY24 $-69.6MFY25 $-127.4M

Operating Income

-52.2% YoY

$-113.5MFY 2025

FY21 $-23.0MFY22 $-53.2MFY24 $-74.6MFY25 $-113.5M

EPS (Diluted)

-30.7% YoY

$-3.19FY 2025

FY21 $-1.87FY22 $-2.10FY24 $-2.44FY25 $-3.19

Total Assets

+380.5% YoY

$349.8MFY 2025

FY21 $175.4MFY22 $135.3MFY24 $72.8MFY25 $349.8M

Op. Cash Flow

-33.0% YoY

$-94.7MFY 2025

FY21 $-27.4MFY22 $-39.1MFY24 $-71.2MFY25 $-94.7M

Metric	FY 2025	FY 2024	FY 2022	FY 2021
Net Income	$-127.4M -83.0%	$-69.6M -35.2%	$-51.5M -124.3%	$-23.0M
Operating Income	$-113.5M -52.2%	$-74.6M -40.1%	$-53.2M -131.2%	$-23.0M
EPS (Diluted)	$-3.19 -30.7%	$-2.44 -16.2%	$-2.10 -12.3%	$-1.87
Total Assets	$349.8M +380.5%	$72.8M -46.2%	$135.3M -22.8%	$175.4M
Operating Cash Flow	$-94.7M -33.0%	$-71.2M -82.0%	$-39.1M -42.8%	$-27.4M

AI Insight: JBIO Financial Trends

JBIO remains pre-revenue with persistent operating losses, but equity surged from -$84M in Q1 2025 to $296M in Q1 2026.

• Equity dramatically improved from -$84M in Q1 2025 to $296M in Q1 2026, indicating significant capital injection.

• Operating cash flow improved from -$37M in Q2 2025 to -$24M in Q1 2026 despite higher operating losses.

• Operating losses worsened from -$3M in Q1 2025 to -$43M in Q1 2026, showing increased cash burn.

⚠ Company remains pre-revenue across all quarters with no clear path to profitability visible in current data.

⚠ Quarterly operating losses show high volatility, ranging from -$3M to -$48M over the past year.

AI Insight: JBIO Ratio Trends

Despite gradual improvement through Q4 2025, JBIO's profitability metrics deteriorated sharply in Q1 2026 with ROA declining to -50.5% from -36.5%.

• ROA improved from -88.7% in Q2 2024 to -36.5% in Q4 2025 before worsening to -50.5% in Q1 2026.

• ROIC showed steady recovery from -94.8% in Q2 2025 to -42.1% in Q4 2025, then declined to -58.6% in Q1 2026.

• ROE exhibited similar pattern, improving to -38.4% in Q4 2025 before reversing to -54.5% in Q1 2026.

⚠ Q1 2026 marked a concerning reversal in profitability trends after three quarters of gradual improvement.

⚠ All profitability metrics remain deeply negative with no clear path to breakeven visibility.

Get alerted when JBIO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Jade Biosciences, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of JBIO

FMR LLC
$99.6M7,085,423 sh
Fairmount Funds Management LLC
$64.0M4,553,494 sh
RA CAPITAL MANAGEMENT, L.P.
$51.6M3,671,083 sh
Bellevue Group AG
$49.2M3,501,502 sh
VR Adviser, LLC
$45.2M3,220,364 sh
JANUS HENDERSON GROUP PLC
$43.6M3,105,669 sh
Avidity Partners Management LP
$34.2M1,400,708 sh
BlackRock, Inc.
$32.5M2,313,949 sh
VANGUARD CAPITAL MANAGEMENT LLC
$25.2M1,796,652 sh
BAKER BROS. ADVISORS LP
$23.1M1,641,137 sh

Fund	Value	Shares
FMR LLC	$99.6M	7,085,423
Fairmount Funds Management LLC	$64.0M	4,553,494
RA CAPITAL MANAGEMENT, L.P.	$51.6M	3,671,083
Bellevue Group AG	$49.2M	3,501,502
VR Adviser, LLC	$45.2M	3,220,364
JANUS HENDERSON GROUP PLC	$43.6M	3,105,669
Avidity Partners Management LP	$34.2M	1,400,708
BlackRock, Inc.	$32.5M	2,313,949
VANGUARD CAPITAL MANAGEMENT LLC	$25.2M	1,796,652
BAKER BROS. ADVISORS LP	$23.1M	1,641,137

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put JBIO on your watchlist

Track score changes the day Jade Biosciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is JBIO a good stock to buy?

13F Pro's AI-powered analysis of Jade Biosciences, Inc. (JBIO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for JBIO are available on the JBIO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own JBIO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling JBIO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Jade Biosciences, Inc.'s investment landscape.